[go: up one dir, main page]

FR2903984B1 - Derives d'imidazolones substitues, preparation et utilisations - Google Patents

Derives d'imidazolones substitues, preparation et utilisations

Info

Publication number
FR2903984B1
FR2903984B1 FR0606752A FR0606752A FR2903984B1 FR 2903984 B1 FR2903984 B1 FR 2903984B1 FR 0606752 A FR0606752 A FR 0606752A FR 0606752 A FR0606752 A FR 0606752A FR 2903984 B1 FR2903984 B1 FR 2903984B1
Authority
FR
France
Prior art keywords
preparation
imidazolone derivatives
substituted
substituted imidazolone
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR0606752A
Other languages
English (en)
Other versions
FR2903984A1 (fr
Inventor
Edith Bouey
Christophe Masson
Karine Bertrand
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genfit SA
Original Assignee
Genfit SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0606752A priority Critical patent/FR2903984B1/fr
Application filed by Genfit SA filed Critical Genfit SA
Priority to US12/309,642 priority patent/US20100004159A1/en
Priority to EA200900211A priority patent/EA200900211A1/ru
Priority to CA002658625A priority patent/CA2658625A1/fr
Priority to KR1020097003832A priority patent/KR20090038469A/ko
Priority to BRPI0715326-0A priority patent/BRPI0715326A2/pt
Priority to PCT/FR2007/051716 priority patent/WO2008012470A2/fr
Priority to EP07823633A priority patent/EP2049107A2/fr
Priority to JP2009521318A priority patent/JP2009544675A/ja
Priority to AU2007279135A priority patent/AU2007279135A1/en
Priority to CNA2007800352070A priority patent/CN101522192A/zh
Priority to MX2009000900A priority patent/MX2009000900A/es
Priority to NZ575011A priority patent/NZ575011A/en
Publication of FR2903984A1 publication Critical patent/FR2903984A1/fr
Application granted granted Critical
Publication of FR2903984B1 publication Critical patent/FR2903984B1/fr
Priority to NO20090348A priority patent/NO20090348L/no
Priority to IL196671A priority patent/IL196671A0/en
Priority to ZA200901268A priority patent/ZA200901268B/xx
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
FR0606752A 2006-07-24 2006-07-24 Derives d'imidazolones substitues, preparation et utilisations Expired - Fee Related FR2903984B1 (fr)

Priority Applications (16)

Application Number Priority Date Filing Date Title
FR0606752A FR2903984B1 (fr) 2006-07-24 2006-07-24 Derives d'imidazolones substitues, preparation et utilisations
CNA2007800352070A CN101522192A (zh) 2006-07-24 2007-07-24 取代的咪唑啉酮衍生物、制备和用途
CA002658625A CA2658625A1 (fr) 2006-07-24 2007-07-24 Derives d'imidazolones substitues, preparation et utilisations
KR1020097003832A KR20090038469A (ko) 2006-07-24 2007-07-24 치환된 이미다졸론 유도체, 그 제조 및 용도
BRPI0715326-0A BRPI0715326A2 (pt) 2006-07-24 2007-07-24 compostos derivados de imidazolonas polissubstituÍdas, composiÇço farmacÊutica e, uso de pelo menos um composto
PCT/FR2007/051716 WO2008012470A2 (fr) 2006-07-24 2007-07-24 Derives d'imidazolones substitues, preparation et utilisations
EP07823633A EP2049107A2 (fr) 2006-07-24 2007-07-24 Derives d'imidazolones substitues, preparation et utilisations
JP2009521318A JP2009544675A (ja) 2006-07-24 2007-07-24 置換されたイミダゾロン誘導体、製造方法及び使用
US12/309,642 US20100004159A1 (en) 2006-07-24 2007-07-24 Substituted imidazolone derivatives, preparations and uses
EA200900211A EA200900211A1 (ru) 2006-07-24 2007-07-24 Замещенные производные имидазолона, их получение и применение
MX2009000900A MX2009000900A (es) 2006-07-24 2007-07-24 Derivados de imidazolonas sustituidas, preparacion y usos.
NZ575011A NZ575011A (en) 2006-07-24 2007-07-24 Substituted imidazolone derivatives, preparation and uses
AU2007279135A AU2007279135A1 (en) 2006-07-24 2007-07-24 Substituted imidazolone derivatives, preparation and uses
NO20090348A NO20090348L (no) 2006-07-24 2009-01-22 Substituerte imidazolonderivater, sammensetninger og anvendelser av samme, samt fremgangsmater for fremstilling av samme
IL196671A IL196671A0 (en) 2006-07-24 2009-01-22 Substituted imidazolone derivatives, preparation and uses
ZA200901268A ZA200901268B (en) 2006-07-24 2009-02-23 Substituted imidazolone derivatives, preparation and uses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0606752A FR2903984B1 (fr) 2006-07-24 2006-07-24 Derives d'imidazolones substitues, preparation et utilisations

Publications (2)

Publication Number Publication Date
FR2903984A1 FR2903984A1 (fr) 2008-01-25
FR2903984B1 true FR2903984B1 (fr) 2008-10-03

Family

ID=37843186

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0606752A Expired - Fee Related FR2903984B1 (fr) 2006-07-24 2006-07-24 Derives d'imidazolones substitues, preparation et utilisations

Country Status (16)

Country Link
US (1) US20100004159A1 (fr)
EP (1) EP2049107A2 (fr)
JP (1) JP2009544675A (fr)
KR (1) KR20090038469A (fr)
CN (1) CN101522192A (fr)
AU (1) AU2007279135A1 (fr)
BR (1) BRPI0715326A2 (fr)
CA (1) CA2658625A1 (fr)
EA (1) EA200900211A1 (fr)
FR (1) FR2903984B1 (fr)
IL (1) IL196671A0 (fr)
MX (1) MX2009000900A (fr)
NO (1) NO20090348L (fr)
NZ (1) NZ575011A (fr)
WO (1) WO2008012470A2 (fr)
ZA (1) ZA200901268B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
CA2793949A1 (fr) * 2010-03-26 2011-09-29 Merck Sharp & Dohme Corp. Nouveaux derives spiro d'imidazolone au titre d'antagonistes de recepteurs de glucagone, compositions, et methodes pour leur utilisation
WO2011157827A1 (fr) 2010-06-18 2011-12-22 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
US8633231B2 (en) 2010-07-13 2014-01-21 Merck Sharp & Dohme Corp. Substituted imidazolones, compositions containing such compounds and methods of use
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
EP3628661A1 (fr) * 2013-06-27 2020-04-01 Lg Chem, Ltd. Dérivés de biaryle en tant qu'agonistes de gpr120
JP6617106B2 (ja) 2013-12-17 2019-12-04 ヤンセン ファーマシューティカ エヌ．ベー． 癌の治療用のｆａｓｎ阻害剤として有用なイミダゾリン−５−オン誘導体
CN105439946B (zh) * 2014-08-13 2018-02-02 益方生物科技（上海）有限公司 羧酸化合物及其制备方法和用途
CN104177298B (zh) * 2014-09-18 2018-10-02 湘潭大学 4,4-二取代-4,5-二氢-1h–咪唑-5-酮、衍生物及其合成方法
US10493046B2 (en) 2015-07-17 2019-12-03 Universite Paris Descartes 5-hydroxytryptamine 1B receptor-stimulating agent for use as a promoter of satellite cells self-renewal and/or differentiation
WO2017043092A1 (fr) * 2015-09-11 2017-03-16 Raqualia Pharma Inc. Dérivés d'imidazolinone utilisés en tant qu'antagonistes de trpm8
DK3436434T3 (da) 2016-03-31 2020-09-21 Oncternal Therapeutics Inc Indolin-analoger og anvendelser deraf
MX2019000600A (es) 2016-07-15 2019-06-13 Pasteur Institut Agente estimulador del receptor 5-hidroxitriptamina 1b para reparación de piel y/o cabello.
CN113121394B (zh) * 2019-12-30 2022-11-08 中国药科大学 一种苯氧乙酸类衍生物的制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0402486A3 (en) * 2001-11-30 2007-05-02 Lilly Co Eli Nitrogen containing heterocyclic compounds as peroxisome proliferator activated receptor agonists, their use and pharmaceutical compositions cointaining them
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
WO2004082621A2 (fr) * 2003-03-15 2004-09-30 Bethesda Pharmaceuticals, Inc. Nouveaux agonistes ppar, compositions pharmaceutiques et leurs utilisations

Also Published As

Publication number Publication date
KR20090038469A (ko) 2009-04-20
JP2009544675A (ja) 2009-12-17
EA200900211A1 (ru) 2009-06-30
MX2009000900A (es) 2009-06-18
CN101522192A (zh) 2009-09-02
ZA200901268B (en) 2010-04-28
IL196671A0 (en) 2009-11-18
US20100004159A1 (en) 2010-01-07
AU2007279135A1 (en) 2008-01-31
BRPI0715326A2 (pt) 2013-08-13
FR2903984A1 (fr) 2008-01-25
CA2658625A1 (fr) 2008-01-31
WO2008012470A2 (fr) 2008-01-31
EP2049107A2 (fr) 2009-04-22
NZ575011A (en) 2011-12-22
NO20090348L (no) 2009-04-24
WO2008012470A3 (fr) 2008-03-20

Similar Documents

Publication Publication Date Title
FR2903984B1 (fr) Derives d'imidazolones substitues, preparation et utilisations
EP2124551A4 (fr) 1,3-dioxanes substitués et leurs utilisations
EP1973405A4 (fr) Derives d'hydroxyalkymarylamide
NL2000371A1 (nl) Chromaan gesubstitueerde benzimidazoolderivaten.
ATE543808T1 (de) 5,6-ring-annelierte indolderivate und ihre verwendung
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
ATE481383T1 (de) 3-aza-bicycloä3.1.0ühexanderivate
EP1976511A4 (fr) Derives d'arylamide fluore
ATE467633T1 (de) 2-aryl-6-phenylimidazoä1,2-aüpyridin-derivate, ihre herstellung und therapeutische verwendung
ATE494290T1 (de) Substituierte 2,5-dihydro-3h-pyrazol-ä4,3-cü- pyridazin-3-on-derivate, ihre herstellung und ihre verwendung als cannibinoid-cb1- rezeptorliganden
EP1905769A4 (fr) Dérivé du benzimidazole à substitution par un hétérocycle
DE602008005634D1 (de) 1,1,1-trifluor-2-hydroxy-3-phenylpropan-derivate
NL1031473A1 (nl) Cyclopentapyridine- en tetrahydrochinolinederivaten.
MA28461B1 (fr) Derives d'heteroaryl- et phenylsulfamoyle substitues
FR15C0005I2 (fr) Composes derives de benzothiazole, compositions et utilisations
ATE507223T1 (de) N-cycloalkyl-carboxamid-, thiocarboxamid- und n- substitutierte carboximidamid-derivate als fungizide
FR2898894B1 (fr) Composes derives de n-(phenethyl)benzamide substitues, preparation et utilisations
FR2884516B1 (fr) Antagonistes npy, preparation et utilisations
DE602007010118D1 (de) 2-substituierte 4-benzylphthalazinonderivate als histamin-h1- und h3-antagonisten
ZA200710169B (en) Piperidin-4-yl-amide derivatives and their use as SST receptor subtype 5 antagonists
ATE458740T1 (de) 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
ATE555785T1 (de) Triazolderivate als smo-antagonisten
ATE471938T1 (de) Substituierte diazaspiroä4.5üdecanderivate und deren verwendung als neurokininantagonisten
ATE472549T1 (de) Octahydropyrroloä3,4-cüpyrrolderivate und ihre verwendung als antivirale mittel
EP1968616A4 (fr) Dérivés du sulindac, utilisation et préparation de ces derniers

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20100331